🏅 FDA Orphan Designation

Kymriah (tisagenlecleucel)

(tisagenlecleucel) Autologous T Cells transduced with lentiviral vector containing a chimeric antigen receptor directed against CD19

Manufacturer: Novartis Pharmaceuticals Corporation

Indicated for:

Precursor T-cell acute lymphoblastic leukemiaOrphan

FDA-Approved Indications (1)

Precursor T-cell acute lymphoblastic leukemiaOrphan Designation

Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

Indications & Usage

Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.